A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Study Number
4712325
Phase
III
Age Group
Adult
Purpose

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

Check your eligibility for this trial
Check now
Full Title

A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel, An Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Product Candidate, verses Investigator's Choice of CD19 CAR T-Cell Therapy in Patients with Relapsed or Refractory Large B-Cell…

ClinicalTrials.Gov ID
NCT07188558

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.